{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:47:20Z","timestamp":1770749240883,"version":"3.50.0"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,22]],"date-time":"2019-04-22T00:00:00Z","timestamp":1555891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.bone.2019.04.010","type":"journal-article","created":{"date-parts":[[2019,4,22]],"date-time":"2019-04-22T11:26:33Z","timestamp":1555932393000},"page":"75-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Pharmacogenomics of osteonecrosis of the jaw"],"prefix":"10.1016","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2920-6523","authenticated-orcid":false,"given":"Guang","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonal","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Issam S.","family":"Hamadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taimour","family":"Langaee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caitrin W.","family":"McDonough","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. Shannon","family":"Holliday","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jatinder K.","family":"Lamba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan S.","family":"Moreb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Katz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2019.04.010_bb0005","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00008571-199608000-00001","article-title":"Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms","volume":"6","author":"Krynetski","year":"1996","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.bone.2019.04.010_bb0010","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2019.04.010_bb0015","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.joms.2006.11.003","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws","volume":"65","author":"Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws AeAoOaMS","year":"2007","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.bone.2019.04.010_bb0020","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.bone.2019.04.010_bb0025","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bone.2019.04.010_bb0030","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20142014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.bone.2019.04.010_bb0035","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1200\/JCO.2007.15.5424","article-title":"Osteonecrosis of the jaw related to bevacizumab","volume":"26","author":"Estilo","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bone.2019.04.010_bb0040","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1016\/j.joms.2011.03.051","article-title":"Nationwide survey for bisphosphonate-related osteonecrosis of the jaws in Japan","volume":"69","author":"Urade","year":"2011","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.bone.2019.04.010_bb0045","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s00432-010-0907-7","article-title":"Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases","volume":"136","author":"Filleul","year":"2010","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.bone.2019.04.010_bb0050","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/j.joms.2018.04.009","article-title":"National survey on bisphosphonate-related osteonecrosis of the jaws in Japan","volume":"76","author":"Shibahara","year":"2018","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.bone.2019.04.010_bb0055","first-page":"447","article-title":"Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer","volume":"24","author":"Stopeck","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.bone.2019.04.010_bb0060","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ctrv.2015.04.007","article-title":"Drug induced osteonecrosis of the jaw","volume":"41","author":"Hamadeh","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bone.2019.04.010_bb0065","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.oraloncology.2012.03.028","article-title":"Bisphosphonate-related osteonecrosis of the jaws\u2014a review","volume":"48","author":"K\u00fchl","year":"2012","journal-title":"Oral Oncol."},{"key":"10.1016\/j.bone.2019.04.010_bb0070","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/jbmr.2693","article-title":"Osteonecrosis of the jaw in the United States Food and Drug Administration's adverse event reporting system (FAERS)","volume":"31","author":"Zhang","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.04.010_bb0075","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.bone.2019.04.010_bb0080","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bonr.2018.06.007","article-title":"Bisphosphonate conjugation for bone specific drug targeting","volume":"9","author":"Farrell","year":"2018","journal-title":"Bone Rep."},{"key":"10.1016\/j.bone.2019.04.010_bb0085","doi-asserted-by":"crossref","first-page":"300","DOI":"10.23736\/S0026-4806.18.05688-4","article-title":"Clodronate in the management of different musculoskeletal conditions","volume":"109","author":"Frediani","year":"2018","journal-title":"Minerva Med."},{"key":"10.1016\/j.bone.2019.04.010_bb0090","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s12306-018-0548-6","article-title":"Antiresorptive drug-related osteonecrosis of the jaws, literature review and 5 years of experience","volume":"103","author":"Bernardi","year":"2019","journal-title":"Musculoskelet. Surg."},{"key":"10.1016\/j.bone.2019.04.010_bb0095","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/jop.12021","article-title":"Bisphosphonates-related osteonecrosis of the jaws: a preliminary study of salivary interleukins","volume":"42","author":"Bagan","year":"2013","journal-title":"J. Oral Pathol. Med."},{"key":"10.1016\/j.bone.2019.04.010_bb0100","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.bonr.2018.03.003","article-title":"Bisphosphonate-related osteonecrosis of the jaw: a mechanobiology perspective","volume":"8","author":"George","year":"2018","journal-title":"Bone Rep."},{"key":"10.1016\/j.bone.2019.04.010_bb0105","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/FPC.0b013e328335729c","article-title":"Bisphosphonates pathway","volume":"21","author":"Gong","year":"2011","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.bone.2019.04.010_bb0110","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/4351327","article-title":"Geranylgeraniol (GGOH) as a mevalonate pathway activator in the rescue of bone cells treated with zoledronic acid: an in vitro study","volume":"2019","author":"Fliefel","year":"2019","journal-title":"Stem Cells Int."},{"key":"10.1016\/j.bone.2019.04.010_bb0115","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1359\/jbmr.1997.12.9.1358","article-title":"Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5\u2032-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro","volume":"12","author":"Frith","year":"1997","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.04.010_bb0120","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The alendronate phase III osteoporosis treatment study group","volume":"333","author":"Liberman","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2019.04.010_bb0125","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0002-9343(99)80134-X","article-title":"Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling","volume":"99","author":"Chesnut","year":"1995","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bone.2019.04.010_bb0130","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2019.04.010_bb0135","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1939-1676.2004.tb02593.x","article-title":"Bisphosphonates and cancer","volume":"18","author":"Milner","year":"2004","journal-title":"J. Vet. Intern. Med."},{"issue":"Suppl. 3","key":"10.1016\/j.bone.2019.04.010_bb0140","first-page":"S1","article-title":"NCCN task force report: bone health in cancer care","volume":"7","author":"Gralow","year":"2009","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.bone.2019.04.010_bb0145","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1684\/bdc.2013.1724","article-title":"Biology of cancer metastasis","volume":"100","author":"Robert","year":"2013","journal-title":"Bull. Cancer"},{"key":"10.1016\/j.bone.2019.04.010_bb0150","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1006\/jsre.2001.6204","article-title":"Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells","volume":"100","author":"Mancino","year":"2001","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.bone.2019.04.010_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10070218","article-title":"The osteoclast in bone metastasis: player and target","volume":"10","author":"Maurizi","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bone.2019.04.010_bb0160","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4103\/aja.aja_12_18","article-title":"Bone-targeted therapies to reduce skeletal morbidity in prostate cancer","volume":"20","author":"Dorff","year":"2018","journal-title":"Asian J. Androl."},{"key":"10.1016\/j.bone.2019.04.010_bb0165","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv338","article-title":"The role of prolactin in bone metastasis and breast cancer cell-mediated osteoclast differentiation","volume":"108","author":"Sutherland","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bone.2019.04.010_bb0170","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17101764","article-title":"What is breast in the bone?","volume":"17","author":"Shemanko","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bone.2019.04.010_bb0175","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.joms.2006.10.061","article-title":"Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia","volume":"65","author":"Mavrokokki","year":"2007","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.bone.2019.04.010_bb0180","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00774-010-0162-7","volume":"28","author":"Yoneda","year":"2010","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.bone.2019.04.010_bb0185","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2008-04-147884","article-title":"Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis","volume":"112","author":"Sarasquete","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bone.2019.04.010_bb0190","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1634\/theoncologist.2011-0202","article-title":"Genomewide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: the role of RBMS3","volume":"17","author":"Nicoletti","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.bone.2019.04.010_bb0195","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/jbmr.3285","article-title":"SIRT1\/HERC4 locus associated with bisphosphonate-induced osteonecrosis of the jaw: an exome-wide association analysis","volume":"33","author":"Yang","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.04.010_bb0200","article-title":"Genetic investigation of bisphosphonate-related osteonecrosis of jaw (BRONJ) via whole exome sequencing and bioinformatics","volume":"10","author":"Kim","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bone.2019.04.010_bb0205","first-page":"579","article-title":"A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer","volume":"6","author":"English","year":"2010","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.bone.2019.04.010_bb0210","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.3324\/haematol.2011.042572","article-title":"CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma","volume":"96","author":"Such","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.bone.2019.04.010_bb0215","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1365-2141.2011.08622.x","article-title":"A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling","volume":"154","author":"Di Martino","year":"2011","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bone.2019.04.010_bb0220","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/odi.12355","article-title":"Genetic association between VEGF polymorphisms and BRONJ in the Korean population","volume":"21","author":"Choi","year":"2015","journal-title":"Oral Dis."},{"key":"10.1016\/j.bone.2019.04.010_bb0225","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1080\/10428194.2017.1300889","article-title":"Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy","volume":"58","author":"Kastritis","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bone.2019.04.010_bb0230","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ijom.2011.02.002","article-title":"Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw","volume":"40","author":"Katz","year":"2011","journal-title":"Int. J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.bone.2019.04.010_bb0235","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jcms.2012.10.018","article-title":"Major histocompatibility complex class II polymorphisms are associated with the development of anti-resorptive agent-induced osteonecrosis of the jaw","volume":"41","author":"Stockmann","year":"2013","journal-title":"J. Craniomaxillofac. Surg."},{"key":"10.1016\/j.bone.2019.04.010_bb0240","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1601-0825.2012.01912.x","article-title":"New approach to analyze genetic and clinical data in bisphosphonate-induced osteonecrosis of the jaw","volume":"18","author":"Balla","year":"2012","journal-title":"Oral Dis."},{"key":"10.1016\/j.bone.2019.04.010_bb0245","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.coms.2015.06.005","article-title":"Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw","volume":"27","author":"Fung","year":"2015","journal-title":"Oral Maxillofac. Surg. Clin. North Am."},{"key":"10.1016\/j.bone.2019.04.010_bb0250","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1600-0714.2010.01004.x","article-title":"Vascular endothelial growth factor genetic polymorphisms and haplotypes in female patients with bisphosphonate-related osteonecrosis of the jaws","volume":"40","author":"Arduino","year":"2011","journal-title":"J. Oral Pathol. Med."},{"key":"10.1016\/j.bone.2019.04.010_bb0255","first-page":"364","article-title":"Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw","volume":"3","author":"Marini","year":"2011","journal-title":"Front. Biosci. (Elite Ed.)"},{"key":"10.1016\/j.bone.2019.04.010_bb0260","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2217\/bmm.12.14","article-title":"An aromatase polymorphism (g.132810C>T) predicts risk of bisphosphonate-related osteonecrosis of the jaw","volume":"6","author":"La Ferla","year":"2012","journal-title":"Biomark. Med"},{"key":"10.1016\/j.bone.2019.04.010_bb0265","first-page":"260","article-title":"The Affymetrix DMET platform and pharmacogenetics in drug development","volume":"11","author":"Deeken","year":"2009","journal-title":"Curr. Opin. Mol. Ther."},{"key":"10.1016\/j.bone.2019.04.010_bb0270","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.tem.2010.08.006","article-title":"PPAR\u03b3 in bone homeostasis","volume":"21","author":"Wan","year":"2010","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.bone.2019.04.010_bb0275","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ebiom.2016.06.040","article-title":"PPARG post-translational modifications regulate bone formation and bone resorption","volume":"10","author":"Stechschulte","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bone.2019.04.010_bb0280","doi-asserted-by":"crossref","DOI":"10.1155\/PPAR\/2006\/64807","article-title":"PPAR gamma activity and control of bone mass in skeletal unloading","volume":"2006","author":"Marie","year":"2006","journal-title":"PPAR Res."},{"key":"10.1016\/j.bone.2019.04.010_bb0285","doi-asserted-by":"crossref","DOI":"10.1155\/PPAR\/2006\/93258","article-title":"The genetics of PPARG and the skeleton","volume":"2006","author":"Ackert-Bicknell","year":"2006","journal-title":"PPAR Res."},{"key":"10.1016\/j.bone.2019.04.010_bb0290","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000087286","article-title":"Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients","volume":"69","author":"Ferretti","year":"2005","journal-title":"Oncology"},{"key":"10.1016\/j.bone.2019.04.010_bb0295","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1006\/cyto.2000.0692","article-title":"Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production","volume":"12","author":"Watson","year":"2000","journal-title":"Cytokine"},{"key":"10.1016\/j.bone.2019.04.010_bb0300","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1159\/000054076","article-title":"A common 936 C\/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels","volume":"37","author":"Renner","year":"2000","journal-title":"J. Vasc. Res."},{"key":"10.1016\/j.bone.2019.04.010_bb0305","doi-asserted-by":"crossref","unstructured":"Brogan IJ, Khan N, Isaac K, Hutchinson JA, Pravica V, Hutchinson IV. Novel polymorphisms in the promoter and 5' UTR regions of the human vascular endothelial growth factor gene. Hum. Immunol. 1999;60:1245\u20139.","DOI":"10.1016\/S0198-8859(99)00132-9"},{"key":"10.1016\/j.bone.2019.04.010_bb0310","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/0378-5122(96)01015-8","article-title":"Estrogen and bone metabolism","volume":"23","author":"V\u00e4\u00e4n\u00e4nen","year":"1996","journal-title":"Maturitas"},{"key":"10.1016\/j.bone.2019.04.010_bb0315","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jsbmb.2006.01.009","article-title":"Estradiol inhibits adhesion and promotes apoptosis in murine osteoclasts in vitro","volume":"99","author":"Saintier","year":"2006","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.bone.2019.04.010_bb0320","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1185\/03007990802352894","article-title":"Modulatory effect of farnesyl pyrophosphate synthase (FDPS) rs2297480 polymorphism on the response to long-term amino-bisphosphonate treatment in postmenopausal osteoporosis","volume":"24","author":"Marini","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.bone.2019.04.010_bb0325","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00210-013-0857-0","article-title":"A novel inhibitory mechanism of nitrogen-containing bisphosphonate on the activity of Cl- extrusion in osteoclasts","volume":"386","author":"Ohgi","year":"2013","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.bone.2019.04.010_bb0330","first-page":"631","article-title":"The role of the mevalonate pathway in osteogenic cells","volume":"12","author":"Ishimi","year":"2002","journal-title":"Clin. Calcium"},{"key":"10.1016\/j.bone.2019.04.010_bb0335","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1056\/NEJMoa0706728","article-title":"Polymorphisms associated with cholesterol and risk of cardiovascular events","volume":"358","author":"Kathiresan","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2019.04.010_bb0340","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1056\/NEJMoa0804742","article-title":"Genotype score in addition to common risk factors for prediction of type 2 diabetes","volume":"359","author":"Meigs","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2019.04.010_bb0345","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.coms.2015.06.001","article-title":"Pathophysiology of osteonecrosis of the jaws","volume":"27","author":"Aghaloo","year":"2015","journal-title":"Oral Maxillofac. Surg. Clin. North Am."},{"key":"10.1016\/j.bone.2019.04.010_bb0350","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.04.010_bb0355","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4103\/2231-0762.178742","article-title":"Medication-related osteonecrosis of the jaw: clinical and practical guidelines","volume":"6","author":"Rosella","year":"2016","journal-title":"J. Int. Soc. Prev. Commun. Dent."},{"key":"10.1016\/j.bone.2019.04.010_bb0360","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1002\/jbmr.1669","article-title":"Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis","volume":"27","author":"Aguirre","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.04.010_bb0365","doi-asserted-by":"crossref","first-page":"e432","DOI":"10.1111\/j.1365-2567.2008.02995.x","article-title":"Major histocompatibility complex (MHC) class II but not MHC class I molecules are required for efficient control of Strongyloides venezuelensis infection in mice","volume":"128","author":"Rodrigues","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.bone.2019.04.010_bb0370","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1124\/pr.115.011411","article-title":"Role of cytochrome P450 2C8 in drug metabolism and interactions","volume":"68","author":"Backman","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bone.2019.04.010_bb0375","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/jbmr.1788","article-title":"Gene-gene interaction between RBMS3 and ZNF516 influences bone mineral density","volume":"28","author":"Yang","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.04.010_bb0380","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jmb.2007.06.006","article-title":"RNA-binding protein RBMS3 is expressed in activated hepatic stellate cells and liver fibrosis and increases expression of transcription factor Prx1","volume":"371","author":"Fritz","year":"2007","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bone.2019.04.010_bb0385","doi-asserted-by":"crossref","first-page":"D930","DOI":"10.1093\/nar\/gkr917","article-title":"HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants","volume":"40","author":"Ward","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bone.2019.04.010_bb0390","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.tig.2014.07.001","article-title":"Ten years of next-generation sequencing technology","volume":"30","author":"van Dijk","year":"2014","journal-title":"Trends Genet."},{"key":"10.1016\/j.bone.2019.04.010_bb0395","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s11626-016-0070-9","article-title":"SIRT1 was involved in TNF-\u03b1-promoted osteogenic differentiation of human DPSCs through Wnt\/\u03b2-catenin signal","volume":"52","author":"Feng","year":"2016","journal-title":"In Vitro Cell. Dev. Biol. Anim."},{"key":"10.1016\/j.bone.2019.04.010_bb0400","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.biopha.2016.05.027","article-title":"Targeting the interaction of Aurora kinases and SIRT1 mediated by Wnt signaling pathway in colorectal cancer: a critical review","volume":"82","author":"Subramaniyan","year":"2016","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bone.2019.04.010_bb0405","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13578-015-0055-5","article-title":"SIRT1 inhibits adipogenesis and promotes myogenic differentiation in C3H10T1\/2 pluripotent cells by regulating Wnt signaling","volume":"5","author":"Zhou","year":"2015","journal-title":"Cell Biosci."},{"key":"10.1016\/j.bone.2019.04.010_bb0410","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.bone.2013.10.020","article-title":"Low sirtuin 1 levels in human osteoarthritis subchondral osteoblasts lead to abnormal sclerostin expression which decreases Wnt\/\u03b2-catenin activity","volume":"59","author":"Abed","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.bone.2019.04.010_bb0415","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1016\/j.bbadis.2015.07.007","article-title":"Suppression of RANKL-induced osteoclast differentiation by cilostazol via SIRT1-induced RANK inhibition","volume":"1852","author":"Park","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bone.2019.04.010_bb0420","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1074\/jbc.M806708200","article-title":"Hyaluronan-mediated CD44 interaction with p300 and SIRT1 regulates beta-catenin signaling and NFkappaB-specific transcription activity leading to MDR1 and Bcl-xL gene expression and chemoresistance in breast tumor cells","volume":"284","author":"Bourguignon","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2019.04.010_bb0425","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/0022034510397196","article-title":"Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN","volume":"90","author":"Barasch","year":"2011","journal-title":"J. Dent. Res."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328219301462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328219301462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:43:16Z","timestamp":1757612596000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328219301462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":85,"alternative-id":["S8756328219301462"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2019.04.010","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacogenomics of osteonecrosis of the jaw","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2019.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}